CX3CL1 at the crossroad of EGF signals

Inflammatory mediators can play a dual role in oncogenesis and tumor progression. CX3CL1, a chemokine previously implicated in natural killer cell- and CD8+ T cell-mediated antitumor immune responses, has now been identified as a promoter of ERBB2-expressing breast carcinomas as it cross-activates members of the epidermal growth factor receptor family.

• Publication year

  2013

• Venue

  Oncoimmunology

• Publication date

  2013-07-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/onci.25669PMID 24319638PMCID 3850216
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CX3CL1 promotes breast cancer via transactivation of the EGF pathway.

  2013cited by this paper
• CCR5 as a potential target in cancer therapy: inhibition or stimulation?

  2012cited by this paper
• In vivo structure/function and expression analysis of the CX3C chemokine fractalkine.

  2011cited by this paper
• Identification of the Chemokine CX3CL1 as a New Regulator of Malignant Cell Proliferation in Epithelial Ovarian Cancer

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma

  2007cited by this paper
• A role for chemokine receptor transactivation in growth factor signaling

  2001cited by this paper
• Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53.

  2000cited by this paper
• EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF

  1999cited by this paper
• Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion

  1997cited by this paper

• Apoptotic cells promote circulating tumor cell survival and metastasis

  2025cites this paper
• Apoptotic cells promote circulating tumor cell survival and metastasis

  2024cites this paper
• Cytotoxic n-Hexane Fraction of the Egyptian Pteris vittata Functions as Anti-breast Cancer Through Coordinated Actions on Apoptotic and Autophagic Pathways

  2023cites this paper
• Cell death, therapeutics, and the immune response in cancer.

  2023cites this paper
• Mechanism of interaction between autophagy and apoptosis in cancer

  2021cites this paper
• Chemokine biology on immune checkpoint-targeted therapies.

  2020cites this paper
• TRAIL receptor signaling: From the basics of canonical signal transduction toward its entanglement with ER stress and the unfolded protein response.

  2020cites this paper
• Apoptosis – Fueling the oncogenic fire

  2020cites this paper
• Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors

  2019cites this paper
• Still Laughing Failures behind the Windows of Cancer Therapeutic Strategies

  2017cites this paper
• Chemokine Receptor Signaling and the Hallmarks of Cancer.

  2017cites this paper
• Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells

  2016cites this paper
• A fate worse than death: apoptosis as an oncogenic process

  2016cites this paper
• Chemokines accentuating protumoral activities in oral cancer microenvironment possess an imperious stratagem for therapeutic resolutions.

  2016cites this paper